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Highlights: 
• In Switzerland, incidence of childhood cancer increased by 18% from 1985-2014. 
• Increase in incidence was mainly caused by brain tumours and leukaemias. 
• Improved registration and diagnostics may have increased brain tumour incidence.  
• Increasing trend for leukaemias may be real, but reasons remain elusive. 
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STRUCTURED ABSTRACT 1 
Background: Incidence of childhood cancer increased in most countries worldwide, but 2 
the reasons are unclear. This study investigates trends in childhood cancer incidence in 3 
Switzerland from 1985 to 2014.  4 
Methods: We extracted data on all childhood cancer cases diagnosed at ages 0-14 5 
years in Switzerland from the Swiss Childhood Cancer Registry. We included ICCC-3 6 
main groups I-XII and calculated age-standardised, cumulative, and age-specific 7 
incidence for different diagnostic groups. We analysed trends in annual age-8 
standardised incidence using JoinPoint regression models.  9 
Results: Over the study period from 1985-2014, 5104 of 5486 cancer diagnoses (93%) 10 
were microscopically verified. The proportion of children treated in paediatric cancer 11 
centres increased from 84% during 1985-1994 to 93% in 1995-2004 and 98% in 2005-12 
2014 (p<0.001). Using the 2010 European standard population, age-standardised 13 
incidence was 143 in 1985-1994, 154 in 1995-2004, and 162 per million in 2005-2014. 14 
Over the period 1985-2014, incidence for all cancers increased by 0.7% (95% 15 
confidence interval [CI] 0.5-1.0) per year, 0.8% (95% CI 0.2%-1.4%) for leukaemias, 16 
3.8% (95% CI 1.7%-6.0%) for epithelial neoplasms and melanomas, and 3.0% (95% CI 17 
1.3%-4.6%) for CNS tumours for the period 1985-2002. 18 
Conclusion: Trends in incidence were driven mostly by increases among leukaemias 19 
and CNS tumours. For CNS tumours, observed trends may be explained at least 20 
partially by diagnostic changes and improved registration. For leukaemias, rising 21 
incidence may be real and at least partly due to changes in risk factors.22 
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MAIN TEXT 1 
Introduction 2 
Incidence of childhood cancer during the decade 2001-2010 increased worldwide by 3 
13% compared to rates in the 1980s.1 The reasons for this increase remain unclear. 4 
Improved case ascertainment and diagnostics could account for this trend,2,3 or the 5 
trend could represent a real increase in cancer risks.4-8 Most countries have seen 6 
increasing trends in childhood cancers, though results vary by reporting period and 7 
cancer type.2,8-20 Switzerland is one of the few countries with a national childhood 8 
cancer registry that has been in existence for over 40 years.21 However, registry data 9 
on incidence of childhood cancer have only been published for the diagnostic period 10 
1995-2005.22,23 Trends in the incidence of childhood cancer over the whole period 11 
have not yet been analysed. 12 
This study is the first to assess long-term trends in incidence of childhood cancer in 13 
Switzerland. The two major aims are to calculate age-standardised, age-specific, and 14 
cumulative incidence for three diagnostic periods—1985-1994, 1995-2004, and 2005-15 
2014—and to describe trends in age-standardised incidence over the entire period 16 
from 1985 to 2014. We also assessed indices of quality of registered cases in the SCCR. 17 
Methods 18 
Study population and procedure 19 
The Swiss Childhood Cancer Registry (SCCR) was founded by the Swiss Paediatric 20 
Oncology Group (SPOG) in 1976 and initially registered patients included in clinical 21 
trials.21 Beginning in 1981, all patients treated in paediatric cancer centres were 22 
systematically included. In a retrospective study covering the period 1990-2004, we 23 
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discovered, however, that 16% of children with cancer had not been treated in 1 
paediatric cancer centres, including infants who were diagnosed only at autopsy in 2 
neonatal departments.24  3 
Between 2004 and 2007, the SCCR was reorganized according to international 4 
recommendations,25,26 and the review of diagnoses using pathology reports, quality 5 
indices, and retrospective inclusion of missed cases were introduced. Since then, the 6 
SCCR improved case completeness by comparing datasets with the population-based 7 
cancer registries of each Swiss canton, and by finding missed cases in mortality 8 
statistics.27 The SCCR includes >95% of all childhood cancer cases diagnosed in 9 
Switzerland since 1995.  10 
A clinical research coordinator in each paediatric cancer centre notifies the SCCR of 11 
new cases within two months of diagnosis. Children diagnosed with cancer before they 12 
reach the age of 16 years and older adolescents diagnosed with typical paediatric 13 
tumours are usually treated in paediatric cancer centres in Aarau, Basel, Bellinzona, 14 
Bern, Geneva, Lausanne, Lucerne, St. Gallen, and Zurich.   15 
For this study, we included all children with Swiss residency at diagnosis who were 16 
registered in the SCCR and diagnosed with cancer according to one of the 12 main 17 
diagnostic groups of the ICCC-3 at ages 0-14 years between 1 January 1985 and 31 18 
December 2014.19 
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Measurements 1 
The SCCR registers patients with leukaemias and lymphomas, malignant and benign 2 
CNS tumours, malignant solid tumours, and Langerhans cell histiocytosis who were 3 
diagnosed at ages under 21 years in Switzerland. The registry records personal 4 
information including name, sex, date of birth, address, nationality; diagnostic 5 
information including exact diagnosis and its date, basis of diagnosis, site and grade of 6 
primary and subsequent tumour(s), histological type and grade, immunophenotype 7 
and genetics, stage at diagnosis, laterality, and site of any metastasis; and treatment 8 
information that includes the name and type of treating institution, treatment type, 9 
study type, and study protocol name. Diagnoses are classified according to the 10 
International Classification of Diseases, tenth revision (ICD-10); topography and 11 
morphology of the ICD for Oncology, third revision (ICD-O-3); and the International 12 
Classification of Childhood Cancer, third edition (ICCC-3).25,28,29 The study was covered 13 
by the Ethics Committee of the Canton of Bern approval to the SCCR (KEK-BE: 14 
166/2014). 15 
Statistical methods 16 
We calculated incidence rates based on population data from the Swiss Federal 17 
Statistical Office.30 To assess indices of quality, we identified cancers treated in 18 
paediatric cancer centres and cancers that had microscopically verified diagnoses that 19 
were confirmed from histology of a primary tumour, haematological examination of 20 
peripheral blood or bone marrow, or histology of metastasis. We then calculated the 21 
average number of cases diagnosed per year and the proportional distribution of ICCC-22 
3 main groups during the three decades 1985-1994, 1995-2004, and 2005-2014. We 23 
calculated incidence rates (IR) for ICCC-3 main groups and subgroups per decade 24 
Trends in Incidence of Childhood Cancer in Switzerland Sommer et al.
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/670224doi: bioRxiv preprint first posted online Jun. 14, 2019; 
PRE-PRINT
expressed per million children,25 with direct standardization for age using the 2010 1 
European standard population.31 We calculated cumulative IR, defined as the sum of 2 
age-specific IR over each year of age from 0 to 14 years and the risk of being diagnosed 3 
with cancer before the age of 15 (1 divided by the cumulative IR). We also computed 4 
age-specific IRs for the age groups <1, 1-4, 5-9, and 10-14 years. The 95% confidence 5 
intervals (95% CI) for the IR were calculated assuming Poisson distribution. We used R 6 
version 3.2.2 for data preparation, descriptive statistics, and calculation of IRs. 7 
We examined trends in annual age-standardised incidence ratios from 1985 to 2014 8 
for all diagnostic groups combined, separately for boys and girls, and for main 9 
diagnostic groups using JoinPoint, Version 4.0.2.2, assessing the magnitude and 10 
direction of trends over time and quantifying the average annual percentage change 11 
(AAPC).11,13,16,19,32-35 JoinPoint fitted straight regression lines through the data, with the 12 
natural logarithm of age-standardised incidence rates as dependent variable and 13 
calendar year (1985-2014) as independent variable. We used a maximum of two 14 
joinpoints to detect a maximum of three different trends, with a minimum of three 15 
years between joinpoints. We selected the trend lines that provided the best fit to 16 
observed age-standardised incidence rates based on the ratio of the sums of squared 17 
errors from the null model and the alternative model. Inference is conducted through 18 
Monte Carlo permutation tests as implemented in the software.33 19 
The study population included 98 patients (2%) who were registered from death 20 
certificate notifications. We had no information on ICCC-3 main group for 12 of these 21 
and lacked dates of diagnosis for 75. We classified patients with missing diagnoses as 22 
having had other malignant neoplasms and imputed dates of diagnosis with the 23 
missforest package for R.36 To generate the missing values we used observed data for 24 
year of birth, sex, cancer diagnosis, and age at death in the imputation model. We 25 
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excluded the 98 cases from all analyses using the specific subgroups of ICCC-3 cancer 1 
diagnoses (Supplemental Table 1). 2 
Results 3 
In 2014 Switzerland had a population of 7.825 million inhabitants, of which 1.225 4 
million were 14 years old or younger. From 1985-2014, the SCCR registered 5486 5 
cancer cases in children aged 0-14 years living in Switzerland (Supplemental Figure 1). 6 
Of those, 5104 (93%) were microscopically verified (Table 1). The proportion of verified 7 
cases of leukaemias has remained at 100% since 1995. Microscopic verification of 8 
cancer was highest in 1995-2004 and then decreased again in 2005-2014. This was due 9 
to decreases in CNS tumours, retinoblastomas, and renal tumours.  10 
The proportion of cancers treated in paediatric cancer centres increased from 84% 11 
during 1985-1994 to 98% for 2005-2014 (Supplemental Table 2). The increase was 12 
largest for CNS tumours and epithelial neoplasms and melanomas; the proportion of 13 
CNS tumours treated in paediatric cancer centres increased from 71% in 1985-1994 to 14 
98% in 2005-2014. 15 
During the decade 1985-1994, 1673 cancer cases were diagnosed at age 0-14 years; 16 
1880 cases were diagnosed in 1995-2004, and 1933 cases in 2005-2014 (Table 1). In all 17 
three decades, the most common cancers were leukaemias (31-34%), CNS tumours 18 
(19-23%), and lymphomas (11-12%) (Table 2). The overall annual age-standardised 19 
incidence rate per million children rose from 143 for 1985-1994 to 162 during 2005-20 
2014 (Table 2, Figure 1). Age-standardised incidence in all three decades was highest 21 
for leukaemias, CNS tumours, and lymphomas, and the overall cumulative incidence 22 
before the age of 14 years rose from 2135 to 2423 per million children from 1985-1994 23 
to 2005-2014.  24 
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Childhood cancer was more common in boys than in girls, with a male to female ratio 1 
of 1.28 during 2005-2014 (Table 2). The male to female ratio was largest for Burkitt’s 2 
lymphoma, 6.71, and smallest for thyroid carcinomas, 0.27 (Supplemental Table 1). 3 
Table 3 lists the age-specific incidences of childhood cancer over the period 2005-2014. 4 
Leukaemias and CNS tumours were among the most common cancers throughout all 5 
age group, neuroblastoma until 4 years, renal tumours from 1-4 years, and lymphoma 6 
from 5-14 years.  7 
Overall, age-standardised childhood cancer incidence increased between 1985-2014 by 8 
0.7% per year (95% CI 0.5%-1.0%), though trends differed between age groups, type of 9 
cancer, and sex (Table 4, Figure 2). This increase was highest for children diagnosed 10 
between the ages of 10 and 14 years. The annual increase of 0.8% (95% CI 0.2%-1.4%) 11 
from 1985-2014 for the incidence of leukaemias was mainly driven by a 1.2% (95% CI 12 
0.4%-2.0%) increase among boys (Table 4). The incidence of CNS tumours increased 13 
annually by 3.0% (95% CI 1.3%-4.6%) from 1985-2002, but not thereafter (Table 4). 14 
Over the entire period, to 2014, the annual increase was 1.4% (95% CI 0.5%-2.4%) for 15 
boys and 1.7% (95% CI 0.7%-2.7%) for girls. Incidence of epithelial neoplasms and 16 
melanomas increased by 3.8% (95% CI 1.7%-6.0%) from 1985-2014, but because they 17 
account for only 3% of all cancer cases (165 of 5486 total cases) this had a very small 18 
effect on the overall trend (Tables 1 and 4).19 
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Discussion 1 
Overall childhood cancer incidence rates significantly increased between 1985-2014 in 2 
Switzerland, mainly driven by leukaemias and CNS tumours. The trend for CNS 3 
tumours plateaued in the 2000s, but continued for leukaemias and epithelial 4 
neoplasms and melanomas. The increase in overall incidence rates was age-5 
dependent, with no increase in preschool children up to age 4, a slight increase in 6 
children 5-9 years old, and a stronger increase in young adolescents 10-14 years old. 7 
International comparison 8 
The proportion of microscopically verified cases in the SCCR is high (>93%), suggesting 9 
excellent validity of cancer diagnoses. This is comparable to validity ranging from 92-10 
98% reported in other European countries,17,37,12,1,38,11 and in Japan (90%),39 the US 11 
(95%),32 and Australia (97%).13 Lower proportions of microscopically verified cases in 12 
certain tumours do not necessarily mean lower data quality, though. For 13 
retinoblastoma, current treatment rarely involves surgical removal of the eye, which 14 
has led to a decreasing proportion of microscopically verified cases from 41% for 1985-15 
1994 to 14% during 2005-2014. Patients with low-grade gliomas and certain high-grade 16 
tumours are increasingly diagnosed with imaging techniques when surgical 17 
intervention puts them at high risk for functional loss; many of these patients do not 18 
undergo any surgery unless it becomes inevitable. The decreasing proportion of 19 
microscopically verified CNS tumours, from 92% during 1985-1994 to 82% during 2005-20 
2014, reflects this. 21 
Supplemental Table 3 compares the relative distribution of diagnostic groups and the 22 
overall age-standardised incidence of childhood cancer in Switzerland to the Piedmont 23 
region in Italy,11 Spain,12 Sweden,9 France,37 Germany,38 Austria,17 Western Europe 24 
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combined,1 USA,40 Canada,41 Australia,13 and Korea.14 The relative distribution of 1 
diagnostic groups was similar to these countries, but age-standardized leukaemia 2 
incidence was among the highest, with higher values observed in only Sweden, 3 
Germany, and Australia. The incidence of neuroblastoma was among the lowest, 4 
excepting only Sweden and Australia. 5 
Overall cancer incidence rates in Switzerland continuously rose over the whole study 6 
period, from 1985-2014. Overall incidence rates increased in all world regions except 7 
sub-Saharan Africa from the 1980s to 2001-2010,1 but have remained stable in 8 
Austria,17 Ireland,18 the USA,19 Canada,16 and Australia13 in more recent time periods 9 
(Supplemental Table 4). The increased incidence of childhood cancer observed in our 10 
study is mainly attributable to leukaemia and CNS tumours. Incidence of leukaemia 11 
increased steadily until 2014 without evidence of a plateau. Most countries also 12 
observed an increase,2,7-9,11-14,18,20 while studies from the USA and Austria reported 13 
stable leukaemia incidence (Supplemental Table 4).17,19,32 Leukaemia incidence in 14 
Canada first increased but levelled off after 1999.16 We observed that incidence of CNS 15 
tumours increased until 2002 and plateaued thereafter, similar to Australia.13 Many 16 
studies found increases over the entire study period,8,11,12,17,20 others found no 17 
increase,14,16,19,32,35,42,43 or even a decrease.35 We also found that incidence of epithelial 18 
neoplasms and melanomas increased over the entire study period, similar to the 19 
USA,10,32 Australia,13 and Korea.14 20 
Possible reasons for increasing trend in incidence 21 
The increased incidence of childhood cancer may be attributable to several factors. 22 
First, improved case registration would increase the observed incidence. Patients with 23 
CNS tumours, with epithelial neoplasms and melanomas, and aged 10-14 years at time 24 
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of cancer diagnosis increasingly have been treated in paediatric oncology centres. 1 
These paediatric oncology centres collaborate closely with the SCCR and actively 2 
report every newly diagnosed child.24 Since 1985, SCCR coverage has improved from 3 
85% to 95%.27 The SCCR has retrospectively registered missed cases, but we cannot 4 
exclude that some of the children with CNS tumours or children treated in earlier 5 
decades in adult facilities escaped registration, and thus that earlier incidence of 6 
childhood cancers is underestimated. Advances in medical diagnostics also may have 7 
increased apparent incidence rates. Imaging techniques have enhanced the capacity to 8 
diagnose otherwise undetected low-grade CNS tumours since the mid-1980s.2,44 9 
Finally, medical and environmental risk factors could have increased the incidence of 10 
some cancers, including leukaemias in particular, which recently have increased in 11 
nearly all countries. Leukaemia and CNS tumours may be associated with exposure to 12 
low-level ionizing radiation,45 which has likely increased in recent decades due to the 13 
increasing use of imaging techniques that rely upon ionizing radiation, especially 14 
computed tomography.46 This might explain the age-dependent pattern of increase. 15 
Other potential risk factors include genetic causes, higher birth weight and parental 16 
age, increased infections, exposure to pesticides and traffic-related air pollution, as 17 
well as parental exposure to benzene.47-49 However, the results of this study do not 18 
allow us to draw conclusions about specific risk factors that may have contributed to 19 
the overall increasing incidence of cancer in general, and specifically of leukaemia and 20 
CNS tumours. 21 
Strengths and limitations of the study 22 
The nationwide, population-based coverage of the SCCR with a high completeness of 23 
registration is a real strength of this study.27 Data quality was high with more than 90% 24 
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of the cases having been microscopically verified. We could include recent diagnostic 1 
years (until 2014) due to the fast reporting and quality control procedures in the 2 
SCCR.21 For the most recent years, the SCCR is in the process of exchanging data with 3 
the cantonal cancer registries. Therefore, we may have underestimated increases in 4 
incidence in the most recent period, although the SCCR missed very few cases in 5 
previous linkages. The sample size was limited by the comparatively small population 6 
of Switzerland, which led to wide confidence intervals for some diagnostic groups. 7 
Results should thus be interpreted cautiously because trends may reflect random 8 
fluctuations in incidence.  9 
Conclusions 10 
Changes in registration procedures and advances in medical diagnostics may explain 11 
the increase observed in the incidence in CNS tumours. For leukaemia, rising incidence 12 
may be real and due to changes in parental lifestyle, infections, pesticide exposure, air 13 
pollution, birth weight, or other risk factors. Future aetiological research should 14 
examine these long-term trends together with changes in medical and environmental 15 
risk factors.16 
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Table 1. Numbers of incident cancers and proportions of microscopically verified cancers among all children diagnosed with cancer in Switzerland at age 0-14 years from 
1985-2014, by diagnostic period 
  1985-1994   1995-2004   2005-2014     
 All cases 
Micros-
copically 
verifieda 
% 95% CI  All cases 
Micros-
copically 
verifieda 
% 95% CI  All cases 
Micros-
copically 
verifieda 
% 95% CI  p-valueb 
All cancers (N=5486) 1673 1539 92.0 90.7; 93.3  1880 1769 94.1 93.0; 95.2  1933 1796 92.9 91.8; 94.1  0.047 
Age at diagnosis                 
0-4 years 804 727 90.4 88.4; 92.5  825 754 91.4 89.5; 93.3  830 755 91.0 89.0; 92.9  0.792 
5-9 years 444 410 92.3 89.9; 94.8  498 475 95.4 93.5; 97.2  509 472 92.7 90.5; 95.0  0.112 
10-14 years 425 402 94.6 92.4; 96.7  557 540 96.9 95.5; 98.4  594 569 95.8 94.2; 97.4  0.182 
ICCC-3 Main diagnostic group                
I. Leukaemias 569 561 98.6 97.6; 99.6  581 581 100   647 647 100   <0.001 
II. Lymphomas 201 200 99.5 98.5; 99.9  225 225 100   214 213 99.5 98.6; 99.9  0.580 
III. CNS tumours 328 275 83.8 79.9; 87.8  429 376 87.6 84.5; 90.8  448 364 81.3 77.6; 84.9  0.033 
IV. Neuroblastoma 134 117 87.3 81.7; 92.9  115 106 92.2 87.3; 97.1  119 112 94.1 89.9; 98.3  0.147 
V. Retinoblastoma 46 19 41.3 27.1; 55.5  53 17 32.1 19.5; 44.6  42 6 14.3 3.7; 24.9  0.020 
VI. Renal tumours 102 99 97.1 93.8; 99.9  98 97 99.0 97.0; 99.9  98 92 93.9 89.1; 98.6  0.135 
VII. Hepatic tumours 18 12 66.7 44.9; 88.4  27 27 100   16 15 94 81.9; 99.9  0.002 
VIII. Bone tumours 73 71 97 93.5; 99.9  95 95 100   79 79 100   0.091 
IX. Soft tissue sarcomas 111 110 99 97.3; 99.9  129 128 99.2 97.7; 99.9  139 139 100   0.555 
X. Germ cell tumours 45 42 93.3 86.0; 99.9  53 52 98.1 94.5; 99.9  57 56 98.2 94.8; 99.9  0.303 
XI. Epithelial neoplasms & melanomas 31 29 93.5 84.9; 99.9  65 63 96.9 92.7; 99.9  69 69 100   0.140 
XII. Other malignant neoplasms 15 4 26.7 4.3; 49.0   10 2 20.0 0.0; 44.8   5 4 80 44.9; 99.9   0.055 
Abbreviations: CI, confidence interval; CNS, central nervous system; ICCC-3, International Classification of Childhood Cancer, third edition. 
aIncludes histology of primary tumours and metastasis, and cytology; bp-value derived from Kruskal-Wallis rank sum test for trend, comparing the numbers of microscopically verified cases between 
the three time periods. 
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Table 2. Incidence of childhood cancer in Switzerland at age 0-14 years from 1985-2014, by diagnostic group and period 
1985-1994 
 Average number 
of cases/year (%) 
ASR per million 
population/year  
(95% CI)a 
CR per million 
population  
(95% CI)b 
1:N 
childrenc 
Male/ 
Femaled 
All cancers 166.6 (100) 143.1 (136.2; 150.0) 2135.3 (2108.8; 2161.8) 468 1.24 
ICCC-3 Main diagnostic group      
I. Leukaemias 56.9 (34.2) 48.8 (44.8; 52.8) 730.3 (714.8; 745.8) 1369 1.29 
II. Lymphomas 20.1 (12.1) 17.3 (14.9; 19.7) 259.2 (249.9; 268.4) 3858 2.14 
III. CNS tumours 32.4 (19.4) 27.8 (24.8; 30.8) 417.1 (405.4; 428.8) 2398 1.17 
IV. Neuroblastoma 13.4 (8.0) 11.5 (9.6; 13.5) 168.9 (161.4; 176.3) 5921 1.27 
V. Retinoblastoma 4.6 (2.8) 4.0 (2.8; 5.1) 58.0 (53.6; 62.4) 17241 0.84 
VI. Renal tumours 10.2 (6.1) 8.8 (7.1; 10.5) 129.8 (123.3; 136.4) 7704 0.76 
VII. Hepatic tumours 1.8 (1.1) 1.6 (0.8; 2.3) 22.9 (20.1; 25.6) 43668 1.25 
VIII. Bone tumours 7.3 (4.4) 6.3 (4.8; 7.7) 94.3 (88.7; 99.9) 10604 1.03 
IX. Soft tissue sarcomas 10.9 (6.5) 9.4 (7.6; 11.1) 139.6 (132.8; 146.3) 7163 1.06 
X. Germ cell tumours 4.4 (2.6) 3.8 (2.7; 4.9) 56.4 (52.1; 60.7) 17730 1.10 
XI. Epithelial neoplasms & melanomas 3.1 (1.9) 2.7 (1.7; 3.6) 39.9 (36.3; 43.5) 25063 1.07 
XII. Other malignant neoplasms 1.5 (0.9) 1.3 (0.6; 1.9) 19.1 (16.6; 21.6) 52356 0.88 
1995-2004 
 Average number 
of cases/year (%) 
ASR per million 
population/year  
(95% CI)a 
CR per million 
population  
(95% CI)b 
1:N 
childrenc 
Male/ 
Femaled 
All cancers 187.5 (100) 153.8 (146.8; 160.8) 2298.9 (2272.2; 2325.6) 435 1.27 
ICCC-3 Main diagnostic group      
I. Leukaemias 57.8 (30.8) 47.4 (43.6; 51.3) 710.3 (695.4; 725.1) 1408 1.40 
II. Lymphomas 22.5 (12.0) 18.1 (15.7; 20.4) 270.6 (261.4; 279.7) 3695 1.81 
III. CNS tumours 42.9 (22.9) 34.8 (31.5; 38.1) 523.4 (510.6; 536.1) 1911 1.25 
IV. Neuroblastoma 11.3 (6.0) 9.9 (8.0; 11.7) 144.6 (137.9; 151.3) 6916 0.92 
V. Retinoblastoma 5.3 (2.8) 4.7 (3.4; 5.9) 68.4 (63.7; 73.0) 14620 0.96 
VI. Renal tumours 9.8 (5.2) 8.2 (6.6; 9.9) 122.5 (116.3; 128.6) 8163 1.00 
VII. Hepatic tumours 2.7 (1.4) 2.3 (1.4; 3.2) 33.9 (30.6; 37.1) 29499 3.50 
VIII. Bone tumours 9.5 (5.1) 7.5 (6.0; 9.0) 112.8 (106.9; 118.7) 8865 0.94 
IX. Soft tissue sarcomas 12.9 (6.9) 10.6 (8.7; 12.4) 157.7 (150.7; 164.7) 6341 1.48 
X. Germ cell tumours 5.3 (2.8) 4.4 (3.2; 5.5) 65.1 (60.6; 69.5) 15361 0.77 
XI. Epithelial neoplasms & melanomas 6.5 (3.5) 5.2 (3.9; 6.4) 77.5 (72.5; 82.4) 12903 0.81 
XII. Other malignant neoplasms 1.0 (0.5) 0.8 (0.3; 1.4) 12.3 (10.4; 14.3) 81301 1.00 
2005-2014 
  Average number of cases/year (%) 
ASR per million 
population/year  
(95% CI)a 
CR per million 
population  
(95% CI)b 
1:N 
childrenc 
Male/ 
Femaled 
All cancers 192.4 (100) 162.3 (155.0; 169.5) 2423.4 (2395.5; 2451.2) 413 1.28 
ICCC-3 Main diagnostic group      
I. Leukaemias 64.3 (33.4) 54.5 (50.3; 58.8) 816.0 (799.8; 832.2) 1225 1.57 
II. Lymphomas 21.3 (11.1) 17.5 (15.2; 19.9) 262.4 (253.2; 271.5) 3811 1.77 
III. CNS tumours 44.5 (23.1) 37.3 (33.9; 40.8) 560.7 (547.3; 574.1) 1783 1.17 
IV. Neuroblastoma 11.9 (6.2) 10.5 (8.6; 12.3) 153.0 (146.0; 160.0) 6536 1.13 
V. Retinoblastoma 4.2 (2.2) 3.7 (2.6; 4.8) 54.1 (49.9; 58.3) 18484 0.83 
VI. Renal tumours 9.7 (5.0) 8.4 (6.7; 10.0) 124.4 (118.1; 130.7) 8039 0.80 
VII. Hepatic tumours 1.6 (0.8) 1.4 (0.7; 2.1) 20.4 (17.9; 23.0) 49020 1.67 
VIII. Bone tumours 7.9 (4.1) 6.5 (5.0; 7.9) 97.1 (91.5; 102.7) 10299 0.88 
IX. Soft tissue sarcomas 13.9 (7.2) 11.6 (9.7; 13.6) 173.9 (166.5; 181.4) 5750 1.36 
X. Germ cell tumours 5.7 (3.0) 4.8 (3.6; 6.1) 71.0 (66.2; 75.8) 14085 1.19 
XI. Epithelial neoplasms & melanomas 6.9 (3.6) 5.6 (4.3; 7.0) 84.0 (78.8; 89.2) 11905 0.60 
XII. Other malignant neoplasms 0.5 (0.3) 0.4 (0.1; 0.8) 6.3 (4.9; 7.7) 158730 1.50 
Abbreviations: ASR, age-standardised incidence rate; CI, confidence interval; CNS, central nervous system; CR, cumulative incidence rate; 
ICCC-3, International Classification of Childhood Cancer, third edition. 
aStandardised according to the 2010 European standard population; bCumulative incidence up to the age of 14 years; cNumber of children 
affected up to the age of 14 years in Switzerland; dmale:female ratio 
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Table 3. Age-specific incidence rate per million population in Switzerland and average cases per year from 2005-2014, by age at diagnosis and diagnostic group 
  Age-specific incidence rate (95% CI)  Average cases per year per million population 
  <1 year 1-4 years 5-9 years 10-14 years  <1 year 1-4 years 5-9 years 10-14 years 
All cancers 
228.3 (195.9; 
264.6) 
209.5 (193.7; 
226.3) 
129.7 (118.6; 
141.5) 
142.0 (130.8; 
154.0)  11.8 43.4 33.7 39.4 
ICCC-3 Main diagnostic group          
I. Leukaemias 36.1 (24.0; 52.2) 99.1 (88.4; 110.8) 43.9 (37.6; 51.0) 32.7 (27.4; 38.7)  1.9 20.5 11.4 9.1 
II. Lymphomas 3.9 (0.8; 11.3) 9.7 (6.5; 13.8) 14.9 (11.3; 19.3) 29.3 (24.4; 35.0)  0.2 2.0 3.9 8.1 
III. CNS tumours 36.1 (24.0; 52.2) 38.3 (31.7; 45.8) 40.6 (34.5; 47.4) 33.6 (28.3; 39.7)  1.9 7.9 10.5 9.3 
IV. Neuroblastoma 65.8 (49.0; 86.5) 18.7 (14.2; 24.1) 1.5 (0.6; 3.4) 1.0 (0.3; 2.5)  3.4 3.9 0.4 0.3 
V. Retinoblastoma 25.8 (15.8; 39.8) 6.4 (3.9; 9.9) 0.5 (0.1; 1.9) 0.0 (0.0; 0.7)  1.3 1.3 0.1 0.0 
VI. Renal tumours 18.1 (9.9; 30.3) 16.7 (12.5; 21.9) 6.4 (4.2; 9.5) 1.4 (0.5; 3.1)  0.9 3.5 1.7 0.4 
VII. Hepatic tumours 7.7 (2.8; 16.8) 2.3 (0.9; 4.6) 0.5 (0.1; 1.9) 0.2 (0.0; 1.3)  0.4 0.5 0.1 0.1 
VIII. Bone tumours 0.0 (0.0; 3.9) 1.6 (0.5; 3.8) 5.6 (3.5; 8.6) 12.5 (9.3; 16.4)  0.0 0.3 1.5 3.5 
IX. Soft tissue sarcomas 11.6 (5.3; 22.0) 12.6 (8.9; 17.2) 9.2 (6.5; 12.8) 13.2 (10.0; 17.2)  0.6 2.6 2.4 3.7 
X. Germ cell tumours 19.4 (10.8; 31.9) 3.5 (1.8; 6.3) 1.8 (0.7; 3.7) 5.8 (3.7; 8.6)  1.0 0.7 0.5 1.6 
XI. Epithelial neoplasms & melanomas 1.3 (0.0; 7.2) 0.3 (0.0; 1.8) 4.4 (2.5; 7.0) 12.0 (8.9; 15.8)  0.1 0.1 1.1 3.3 
XII. Other malignant neoplasms 2.6 (0.3; 9.3) 0.3 (0.0; 1.8) 0.3 (0.0; 1.4) 0.2 (0.0; 1.3)   0.1 0.1 0.1 0.1 
Abbreviations: CI, confidence interval; CNS, central nervous system; ICCC-3, International Classification of Childhood Cancer, third edition. 
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Table 4. Average annual percentage change (AAPC) in incidence rates of childhood cancer by diagnostic group, age and sex in 
Switzerland 1985-2014: Results from JoinPoint regression. 
    Trend 1   Trend 2 
Diagnostic group Period AAPC (95% CI)   Period AAPC (95% CI) 
All cancers 1985-2014 0.7 (0.5; 1.0)    
 0-4 years 1985-2014 0.3 (-0.1; 0.7)    
 5-9 years 1985-2014 0.8 (0.2; 1.3)    
 10-14 years 1985-2014 1.4 (0.9; 2.0)    
 I. Leukaemias 1985-2009 0.8 (0.2; 1.4)    
 II. Lymphomas 1985-2014 0.0 (-0.9; 1.0)    
 III. CNS tumours 1985-2002 3.0 (1.3; 4.6)  2002-2014 -0.2 (-2.4; 2.1) 
 IV. Neuroblastoma 1985-2014 -0.5 (-1.7; 0.7)    
 V. Retinoblastoma 1985-2014 -0.9 (-3.0; 1.2)    
 VI. Renal tumours 1985-2014 -0.3 (-1.5; 0.9)    
 VII. Hepatic tumours 1985-2014 n.a.    
 VIII. Bone tumours 1985-2014 0.2 (-0.9; 1.4)    
 IX. Soft tissue sarcomas 1985-2014 1.0 (-0.4; 2.5)    
 X. Germ cell tumours 1985-2014 1.6 (-0.2; 3.4)    
 XI. Epithelial neoplasms & melanomas 1985-2014 3.8 (1.7; 6.0)    
 XII. Other malignant neoplasms 1985-2014 n.a.    
       
Boys      
 All cases 1985-2014 0.8 (0.5; 1.2)    
 I. Leukaemias 1985-2010 1.2 (0.4; 2.0)    
 II. Lymphomas 1985-2014 0.0 (-1.1; 1.0)    
 III. CNS tumours 1985-2014 1.4 (0.5; 2.4)    
 IV. Neuroblastoma 1985-2014 -1.1 (-2.3; 0.1)    
 V. Retinoblastoma 1985-2014 n.a.    
 VI. Renal tumours 1985-2014 0.1 (-1.9; 2.1)    
 VII. Hepatic tumours 1985-2014 n.a.    
 VIII. Bone tumours 1985-2014 n.a.    
 IX. Soft tissue sarcomas 1985-2014 0.7 (-0.8; 2.2)    
 X. Germ cell tumours 1985-2014 n.a.    
 XI. Epithelial neoplasms & melanomas 1985-2014 n.a.    
 XII. Other malignant neoplasms 1985-2014 n.a.    
       
Girls      
 All cases 1985-2014 0.6 (0.2; 1.0)    
 I. Leukaemias 1985-2014 0.2 (-0.6; 0.9)    
 II. Lymphomas 1985-2014 0.1 (-1.8; 2.0)    
 III. CNS tumours 1985-2014 1.7 (0.7; 2.7)    
 IV. Neuroblastoma 1985-2014 0.6 (-1.3; 2.6)    
 V. Retinoblastoma 1985-2014 n.a.    
 VI. Renal tumours 1985-2014 -0.7 (-2.4; 1.1)    
 VII. Hepatic tumours 1985-2014 n.a.    
 VIII. Bone tumours 1985-2014 0.7 (-0.9; 2.5)    
 IX. Soft tissue sarcomas 1985-2014 n.a.    
 X. Germ cell tumours 1985-2014 n.a.    
 XI. Epithelial neoplasms & melanomas 1985-2014 n.a.    
  XII. Other malignant neoplasms 1985-2014 n.a.       
Abbreviations:  AAPC, average annual percentage change; CI, confidence interval; CNS, central nervous system; n.a., not applicable.  
Bold letters indicate AAPCs with p-values<0.05. 
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Figure legends 
 
Figure 1. Comparison of incidence of childhood cancer between 1985-1994, 1995-2004 and 
2005-2014, by cancer diagnosis. 
Abbreviations: ASR, Age-standardized incidence rate.  
Cancer diagnoses were classified according to the International Classification of Childhood 
Cancer, third edition (ICCC-3). Incidence rates were age-standardized according to the 2010 
European standard population. Error bars show 95% confidence intervals. 
 
 
 
 
Figure 2. Trends in incidence rates (per million person-years) in Switzerland between 1985 
and 2014, standardized according to the 2010 European standard population, for A) all 
childhood cancer diagnoses combined and B) leukaemias. Trends were modelled using 
Joinpoint regression.  
Abbreviations: AAPC, average annual percentage change; CI, confidence interval. 
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Supplemental Figure 1. Flow diagram from the number of registered cases in the SCCR to those eligible for the study. 
Abbreviations: ICCC-3, International Classification of Childhood Cancer, third edition. 
 
Supplemental Table 1a. Incidence of childhood cancer in Switzerland at age 0-14 years from 2005-2014, by main diagnostic group and subgroup* 
Diagnostic group/subgroup 
Average 
number of 
cases/year (%) 
ASR per million 
population/year  
(95% CI)a 
CR per million 
population  
(95% CI)b 
1:N 
childrenc 
Male/ 
Femaled 
All cancers 191.4 (100) 161.4 (154.2; 168.7) 2410.6 (2382.8; 2438.4) 415 1.28 
      
I. Leukaemias 64.3 (33.6) 54.5 (50.3; 58.8) 816.0 (799.8; 832.2) 1225 1.57 
a. Lymphoid leukaemias 51.7 (27.0) 43.9 (40.1; 47.7) 657.3 (642.8; 671.9) 1521 1.47 
b. Acute myeloid leukaemias 7.8 (4.1) 6.6 (5.1; 8.1) 98.4 (92.8; 104.0) 10163 1.89 
c. Chronic myeloproliferative diseases 0.9 (0.5) 0.7 (0.3; 1.2) 11.1 (9.2; 13.0) 90090 3.50 
d. Myelodysplastic syndrome and other myeloproliferative diseases 3.2 (1.7) 2.7 (1.8; 3.6) 40.3 (36.7; 43.9) 24814 3.00 
e. Unspecified and other specified leukaemias 0.7 (0.4) 0.6 (0.2; 1.0) 8.9 (7.2; 10.6) 112360 0.75 
      
II. Lymphomas 21.2 (11.1) 17.5 (15.1; 19.8) 261.1 (251.9; 270.2) 3830 1.75 
a. Hodgkin lymphomas 9.6 (5.0) 7.8 (6.2; 9.3) 115.7 (109.6; 121.8) 8643 0.88 
b. Non-Hodgkin lymphomas (except Burkitt lymphoma) 5.7 (3.0) 4.7 (3.5; 6.0) 71.0 (66.2; 75.8) 14085 2.80 
c. Burkitt lymphoma 5.4 (2.8) 4.5 (3.3; 5.7) 68.0 (63.3; 72.6) 14706 6.71 
d. Miscellaneous lymphoreticular neoplasms 0.5 (0.3) 0.4 (0.1; 0.8) 6.4 (5.0; 7.9) 156250 0.25 
      
III. CNS tumours 43.9 (22.9) 36.8 (33.4; 40.3) 553.0 (539.7; 566.4) 1808 1.17 
a. Ependymomas and choroid plexus tumour 4.8 (2.5) 4.1 (3.0; 5.3) 61.1 (56.7; 65.6) 16367 1.29 
b. Astrocytomas 18.4 (9.6) 15.4 (13.1; 17.6) 231.2 (222.6; 239.8) 4325 1.07 
c. Intracranial and intraspinal embryonal tumours 8.0 (4.2) 6.8 (5.3; 8.2) 101.8 (96.1; 107.5) 9823 1.35 
d. Other gliomas 5.1 (2.7) 4.3 (3.1; 5.5) 64.9 (60.4; 69.5) 15408 1.32 
e. Other specified intracranial and intraspinal neoplasms 6.7 (3.5) 5.5 (4.2; 6.8) 82.8 (77.6; 87.9) 12077 1.16 
f. Unspecified intracranial and intraspinal neoplasms 0.9 (0.5) 0.8 (0.3; 1.2) 11.2 (9.3; 13.1) 89286 0.80 
      
IV. Neuroblastoma 11.8 (6.2) 10.4 (8.5; 12.2) 151.7 (144.7; 158.7) 6592 1.11 
a. Neuroblastoma and ganglioneuroblastoma 11.8 (6.2) 10.4 (8.5; 12.2) 151.7 (144.7; 158.7) 6592 1.11 
b. Other peripheral nervous cell tumour 0           
V. Retinoblastoma 4.2 (2.2) 3.7 (2.6; 4.8) 54.1 (49.9; 58.3) 18484 0.83 
      
VI. Renal tumours 9.7 (5.1) 8.4 (6.7; 10.0) 124.4 (118.1; 130.7) 8039 0.80 
a. Nephroblastoma and other nonepithelial renal tumours 9.2 (4.8) 7.9 (6.3; 9.6) 118.3 (112.1; 124.5) 8453 0.80 
b. Renal carcinomas 0.5 (0.3) 0.4 (0.1; 0.8) 6.1 (4.7; 7.5) 163934 0.67 
c. Unspecified renal tumours 0           
VII. Hepatic tumours 1.5 (0.8) 1.3 (0.6; 2.0) 19.1 (16.7; 21.6) 52356 2.00 
a. Hepatoblastoma 1.4 (0.7) 1.2 (0.6; 1.9) 18.0 (15.6; 20.4) 55556 1.80 
b. Hepatic carcinomas 0.1 (0.1) 0.1 (0.0; 0.2) 1.2 (0.5; 1.8) 833333 n.a. 
c. Unspecified hepatic tumours 0         
  
Supplemental Table 1b (continued). Incidence of childhood cancer in Switzerland at age 0-14 years from 2005-2014, by main diagnostic group and subgroup* 
Diagnostic group/ subgroup 
Average 
number of 
cases/year (%) 
ASR per million 
population/year  
(95% CI)a 
CR per million 
population  
(95% CI)b 
1:N 
childrenc 
Male/ 
Femaled 
      
VIII. Bone tumours 7.9 (4.1) 6.5 (5.0; 7.9) 97.1 (91.5; 102.7) 10299 0.88 
a. Osteosarcomas 3.8 (2.0) 3.1 (2.1; 4.1) 46.6 (42.7; 50.4) 21459 0.90 
b. Chondrosarcomas 0.1 (0.1) 0.1 (-0.1; 0.2) 1.2 (0.5; 1.8) 833333 n.a. 
c. Ewing tumour and related sarcomas of bone 3.9 (2.0) 3.2 (2.2; 4.2) 48.2 (44.3; 52.2) 20747 0.95 
d. Other specified bone tumours 0     
e. Unspecified malignant bone tumours 0.1 (0.1) 0.1 (0.0; 0.2) 1.2 (0.5; 1.8) 833333 n.a. 
      
IX. Soft tissue sarcomas 13.9 (7.3) 11.6 (9.7; 13.6) 173.9 (166.5; 181.4) 5750 1.36 
a. Rhabdomyosarcomas 7.8 (4.1) 6.6 (5.1; 8.1) 98.5 (92.9; 104.1) 10152 1.36 
b. Fibrosarcomas, peripheral nerve sheath tumours, other fibrous neoplasms 1.0 (0.5) 0.8 (0.3; 1.3) 12.3 (10.3; 14.3) 81301 2.33 
c. Kaposi sarcoma 0     
d. Other specified soft tissue sarcomas 4.0 (2.1) 3.3 (2.3; 4.3) 49.4 (45.4; 53.4) 20243 0.90 
e. Unspecified soft tissue sarcomas 1.1 (0.6) 0.9 (0.4; 1.5) 13.8 (11.7; 15.9) 72464 4.50 
      
X. Germ cell tumours 5.7 (3.0) 4.8 (3.6; 6.1) 71.0 (66.2; 75.8) 14085 1.19 
a. Intracranial and intraspinal germ cell tumours 1.5 (0.8) 1.2 (0.6; 1.9) 18.5 (16.1; 21.0) 54054 2.00 
b. Malignant extracranial and extragonadal germ cell tumours 1.7 (0.9) 1.5 (0.8; 2.2) 21.9 (19.2; 24.5) 45662 0.70 
c. Malignant gonadal germ cell tumours 2.4 (1.3) 2.0 (1.2; 2.8) 29.3 (26.3; 32.4) 34130 1.18 
d. Gonadal carcinomas 0     
e. Other and unspecified malignant gonadal tumours 0.1 (0.1) 0.1 (0.0; 0.3) 1.3 (0.6; 1.9) 769231 n.a. 
      
XI. Epithelial neoplasms & melanomas 6.9 (3.6) 5.6 (4.3; 7.0) 84.0 (78.8; 89.2) 11905 0.60 
a. Adrenocortical carcinomas 0.2 (0.1) 0.2 (0.0; 0.4) 2.5 (1.6; 3.4) 400000 1.00 
b. Thyroid carcinomas 1.4 (0.7) 1.1 (0.5; 1.7) 16.8 (14.5; 19.1) 59524 0.27 
c. Nasopharyngeal carcinomas 0.2 (0.1) 0.2 (0.0; 0.4) 2.4 (1.5; 3.2) 416667 1.00 
d. Malignant melanomas 1.5 (0.8) 1.2 (0.6; 1.9) 18.5 (16.0; 20.9) 54054 0.50 
e. Skin carcinomas 0.6 (0.3) 0.5 (0.1; 0.9) 7.5 (6.0; 9.1) 133333 2.00 
f. Other and unspecified carcinomas 3.1 (1.6) 2.5 (1.6; 3.4) 37.5 (34.1; 41.0) 26667 0.63 
      
XII. Other malignant neoplasms 0.4 (0.2) 0.3 (0.0; 0.7) 5.0 (3.8; 6.3) 200000 n.a. 
a. Other specified malignant tumours 0.2 (0.1) 0.2 (0.0; 0.4) 2.6 (1.7; 3.5) 384615 1.00 
b. Other unspecified malignant tumours 0.1 (0.1) 0.1 (0.0; 0.3) 1.3 (0.6; 1.9) 769231 n.a. 
Abbreviations: ASR, age-standardised incidence rate; CI, confidence interval; CNS, central nervous system; CR, cumulative incidence rate. 
* Analyses exclude 98 cases from death certificate notifications because data on specific diagnostic subgroups was not available. 
a Standardised according to the 2010 European standard population; b Cumulative incidence up to the age of 14 years; c Number of children affected up to the age of 14 years in Switzerland; d male:female 
ratio. 
 
 
Supplemental Table 2. Proportions of patients treated in paediatric cancer centresa among all children diagnosed with cancer in Switzerland at age 0-14 years from 
1985-2014, by diagnostic period 
  1985-1994   1995-2004   2005-2014     
  All cases 
Paediatric 
cancer 
centresa 
% 95% CI   All cases 
Paediatric 
cancer 
centresa 
% 95% CI   All cases 
Paediatric 
cancer 
centresa 
% 95% CI   p-valueb 
All cancers (N=5486) 1673 1407 84.1 82.3; 85.9  1880 1748 93.0 91.8; 94.1  1933 1891 97.8 97.2; 98.5  <0.001 
Age at diagnosis                 
0-4 years 804 689 85.7 83.3; 88.1  825 791 95.9 94.5; 97.2  830 818 98.6 97.7; 99.4  <0.001 
5-9 years 444 372 83.8 80.4; 87.2  498 469 94.2 92.1; 96.2  509 496 97.4 96.1; 98.8  <0.001 
10-14 years 425 346 81.4 77.7; 85.1  557 488 87.6 84.9; 90.3  594 577 97.1 95.8; 98.5  <0.001 
ICCC-3 Main diagnostic group                
I. Leukaemias 569 518 91.0 88.7; 93.4  581 567 97.6 96.3; 98.8  647 644 100 99.0; 99.9  <0.001 
II. Lymphomas 201 179 89.1 84.7; 93.4  225 213 94.7 91.7; 97.6  214 211 98.6 97.0; 99.9  <0.001 
III. CNS tumours 328 234 71.3 66.4; 76.2  429 390 90.9 88.2; 93.6  448 437 97.5 96.1; 99.0  <0.001 
IV. Neuroblastoma 134 117 87.3 81.7; 92.9  115 113 98.3 95.9; 99.9  119 118 99 97.5; 99.9  <0.001 
V. Retinoblastoma 46 41 89.1 80.1; 98.1  53 49 92.5 85.3; 99.6  42 40 95.2 88.8; 99.9  0.566 
VI. Renal tumours 102 99 97.1 93.8; 99.9  98 97 99.0 97.0; 99.9  98 98 100   0.186 
VII. Hepatic tumours 18 11 61.1 38.6; 83.6  27 27 100   16 15 94 81.9; 99.9  <0.001 
VIII. Bone tumours 73 63 86.3 78.4; 94.2  95 91 95.8 91.8; 99.8  79 79 100   <0.001 
IX. Soft tissue sarcomas 111 93 83.8 76.9; 90.6  129 115 89.1 83.8; 94.5  139 136 97.8 95.4; 99.9  <0.001 
X. Germ cell tumours 45 37 82.2 71.1; 93.4  53 51 96.2 91.1; 99.9  57 54 94.7 88.9; 99.9  0.026 
XI. Epithelial neoplasms & melanomas 31 11 35.5 18.6; 52.3  65 30 46.2 34.0; 58.3  69 55 79.7 70.2; 89.2  <0.001 
XII. Other malignant neoplasms 15 4 26.7 4.3; 49.0   10 5 50.0 19.0; 81.0   5 4 80 44.9; 99.9   0.107 
Abbreviations: CI, confidence interval; CNS, central nervous system; ICCC-3, International Classification of Childhood Cancer, third edition. 
aIncludes the nine clinics of the Swiss Paediatric Oncology Group, bp-value derived from Kruskal-Wallis rank sum test for trend, comparing patient numbers treated in paediatric cancer centres 
between the three time periods. 
 
Supplemental Table 3. Incidence rates of childhood cancer per one million children in Switzerland, other European countries, the USA, Canada, Australia and Korea 
Country Switzerland Piedmont, Italy Spain Sweden France Germany Austria 
Western 
Europe USA Canada Australia Korea 
Period 1985-1994 1995-2004 2005-2014 1967-2011 1982-2002 1990-1998 2000-2004 2005-2014 2009-2011 2001-2010 2000-2013 2006-2010 1997-2006 1999-2011 
First author,  
year of publication 
Sommer,  
2018 
Isaevska, 
2017 
Peris-
Bonet, 
2010 
Dreifaldt, 
2004 
Lacour, 
2010 
Kaatsch, 
2014 
Karim-Kos, 
2016 
Steliarova-
Foucher, 
2017 
US Cancer 
Statistics, 
2016 
Statistics 
Canada, 
2015 
Baade, 
2010 
Park,  
2016 
               
All cancers 143 154 162 157 156 173 157 167 169 n.i. 167 161 158 135 
ICCC-3 Main diagnostic groups               
I. Leukaemias 49 47 55 51 46 51 46 57 54 51 54 52 53 46 
II. Lymphomas 17 18 18 19 18 19 17 16 14 16 17 18 15 13 
III. CNS tumours 28 35 37 37 33 49 36 40 44 38 35 31 36 18 
IV. Neuroblastoma 12 10 11 12 15 11 15 14 12 13 13 13 10 12 
V. Retinoblastoma 4 5 4 4 5 5 5 4 5 5 5 n.i. 4 5 
VI. Renal tumours 9 8 8 7 8 10 10 10 9 10 10 n.i. 9 6 
VII. Hepatic tumours 2 2 1 2 2 3 1 2 1 2 3 n.i. 3 3 
VIII. Bone tumours 6 8 7 9 8 5 7 6 10 7 6 n.i. 7 7 
IX. Soft tissue sarcomas 9 11 12 9 10 8 10 10 10 10 11 10 8 7 
X. Germ cell tumours 4 4 5 4 4 5 6 5 5 5 5 5 6 10 
XI. Other epithelial neoplasms 3 5 6 4 6 4 4 n.i. 7 4 6 n.i. 7 5 
XII. Other malignant neoplasms 1 1 0.4 0.8 0.5 5 0.3 0.2 0 0.3 0.7 n.i. 0.4 3 
Abbreviations: CNS, central nervous system; ICCC-3, International Classification of Childhood Cancer, third edition; n.i., not indicated. 
Supplemental Table 4a. Average annual percentage change (95% CI) of childhood cancer in Switzerland, other European countries, the USA, Canada, Australia, Korea and China 
Country Switzerland Sweden Great Britain Piedmont, Italy Spain Western Germany Eastern Germany Austria Ireland 
Period 1985-2014 1960-1998 1966-2005 1976-2011 1983-2002 1987-2004 1991-2004 1994-2011 1994-2011 
First author,  
year of publication 
Sommer,  
2018 
Dreifaldt,  
2004 
Kroll,  
2012 
Isaevska,  
2017 
Peris-Bonet,  
2010 
Spix,  
2008 
Spix,  
2008 
Karim-Kos,  
2016 
National Cancer 
Registry Ireland, 
2014 
All cancers 0.7 (0.5; 1.0) 1.0 (0.8; 1.2) 1.0 (0.9; 1.1) 1.1 (0.8; 1.5) 1.9 (1.5; 2.4) 0.8 (0.6; 1.1) 2.1 (1.2; 2.9) 0.7 (-0.2; 1.7) 
Girls:  
0.8 (-0.2; 1.8) 
Boys:  
0.6 (-0.8; 2.0) 
I. Leukaemias 0.8 (0.2; 1.4) 0.9 (0.4; 1.3) 0.7 (0.6; 0.9) 0.6 (0.0; 1.2) 
ALL and AML 
combined:  
1.6 (0.8; 2.3) 
0.6 (0.2; 1.1) 2.1 (0.7; 3.5) 0.3 (-0.8; 1.4) 0.7 (-1.0; 2.4) 
II. Lymphomas 0.0 (-0.9; 1.0) 1.9 (1.2; 2.6) 0.8 (0.6; 1.1) 
1976-2007:  
1.7 (0.6; 2.7) 
2007-2011:  
-12.2 (-33.2; 15.4) 
0.9 (0.2; 1.6) -0.9 (-3.0; 1.2) -0.7 (-2.2; 0.8) -1.3 (-3.8; 1.3) 
III. CNS tumours 
1985-2002:  
3.0 (1.3; 4.6) 
2000-2014:  
-0.2 (-2.4; 2.1) 
1.5 (1.0; 1.9) 1.3 (1.2; 1.5) 1.8 (0.9; 2.7) 2.2 (1.2; 3.2) 1.1 (0.6; 1.6) 5.5 (4.6; 7.4) 2.9 (0.9; 5.0) 
1994; 1999:  
-6.3 (-12.9; 0.7) 
1999; 2011:  
2.7 (0.7; 4.7) 
IV. Neuroblastoma -0.5 (-1.7; 0.7) 1.6 (0.8; 2.4) 0.6 (0.4; 0.9) 1.2 (0.2; 2.1) n.i. 0.1 (-1.6; 1.8) 2.3 (-0.8; 5.5) -4.1 (-9.8; 1.6) n.i. 
V. Retinoblastoma -0.9 (-3.0; 1.2) 0.3 (-1.2; 1.7) 0.6 (0.2; 1.1) 0.7 (-11.1; 14.2) n.i. -0.8 (-2.5; 1.0) n.a. n.a. n.i. 
VI. Renal tumours -0.3 (-1.5; 0.9) 0.3 (-0.5; 1.1) 0.7 (0.4; 1.0) 0.2 (-1.1; 1.5) n.i. 0.6 (-0.4; 1.6) 1.8 (-1.5; 5.2) 0.7 (-2.3; 3.7) n.i. 
VII. Hepatic tumours n.a. 2.6 (2.0; 3.2) 2.5 (1.7; 3.3) 3.8 (-13.4; 24.4) n.i. 1.5 (-0.9; 3.9) n.a. n.a. n.i. 
VIII. Bone tumours 0.2 (-0.9; 1.4) 0.2 (-0.8; 1.3) 0.5 (0.2; 0.9) 0.0 (-4.1; 4.4) n.i. -0.1 (-1.3; 1.0) 0.6 (-2.9; 4.3) -0.2 (-3.3; 2.8) n.i. 
IX. Soft tissue sarcomas 1.0 (-0.4; 2.5) 0.1 (-0.8; 1.0) 1.6 (1.3; 1.9) 0.5 (-0.7; 1.7) n.i. 1.3 (0.3; 2.3) -0.6 (-3.7; 2.6) 0.6 (-1.9; 3.0) n.i. 
X. Germ cell tumours 1.6 (-0.2; 3.4) 1.2 (0.2; 2.2) 1.1 (0.6; 1.6) 2.4 (-5.9; 11.5) n.i. -0.2 (-1.5; 1.1) -1.1 (-5.6; 3.5) 2.4 (-2.3; 7.0) n.i. 
XI. Epithelial neoplasms & melanomas 3.8 (1.7; 6.0) 0.0 (-1.1; 1.1) 1.8 (1.3; 2.3) 3.9 (-1.4; 9.5) n.i. 2.0 (-0.7; 4.8) n.a. n.a. n.i. 
XII. Other malignant neoplasms n.a. 0.4 (0.01; 0.9) 2.2 (1.2; 3.2) n.a. n.i. n.a. n.a. n.a. n.i. 
 
  
Supplemental Table 4b (continued). Average annual percentage change (95% CI) of childhood cancer in Switzerland, other European countries, the USA, Canada, Australia, Korea and China 
Country USA USA USA Canada Australia Korea China 
Period 1975-2002 1992-2004 2001-2009 1992-2006 1997-2006 1999-2011 2000-2010 
First author,  
year of publication 
Ward,  
2006 
Linabery,  
2006 
Siegel,  
2014 
Mitra,  
2012 
Baade,  
2010 
Park,  
2016 
Zheng,  
2015 
All cancers 0.7* 0.4 (-0.1; 0.8) 0.3 (-0.1; 0.7) 0.0 (-0.5; 0.4) 
1983-1994:  
1.7 (0.9; 2.5) 
1994-2006:  
-0.1 (-0.7; 0.6) 
2.4 (2.1; 2.7) 2.8 (1.1; 4.6) 
I. Leukaemias 0.7* 0.7 (-0.1; 1.5) 0.5 (-0.3; 1.3) 
1992-1999:  
2.4 (0.0; 4.9) 
1999-2002:  
-4.4 (-20.1; 14.2) 
2002-2006:  
-3.0 (-2.6; 9.0) 
0.9 (0.3; 1.5) increase‡ n.i. 
II. Lymphomas  -0.5* stable‡ 0.5 (-0.2; 1.3) 0.0 (-1.4; 1.4) 0.7 (0.0; 1.3) increase‡ n.i. 
III. CNS tumours 1.2* -0.1 (-1.1; 1.0) -0.1 (-1.0; 0.8) -0.4 (-1.3; 0.5) 
1983-1998:  
1.7 (0.6; 2.8) 
1998-2006:  
-1.8 (-4.5; 1.0) 
stable‡ n.i. 
IV. Neuroblastoma 0.5 -0.6 (-2.9; 1.7) -1.2 (-3.0; 0.8) -0.2 (-1.8; 1.5) 0.2 (-1.1; 1.4) 5.6* n.i. 
V. Retinoblastoma 0.5 0.3 (-1.5; 2.1) -0.2 (-1.8; 1.5) -2.6 (-4.7; -0.4) 0.2 (-1.1; 1.4) stable‡ n.i. 
VI. Renal tumours 0.4 -2.1 (-4.6; 0.4) 0.5 (-0.3; 1.3) -1.3 (-3.2; 0.7) 0.4 (-0.7; 1.6) stable‡ n.i. 
VII. Hepatic tumours 2.0* 4.3 (0.2; 8.7) 1.7 (-1.7; 5.3) 1.6 (-0.8; 4.0) 3.3 (0.8; 5.9) stable‡ n.i. 
VIII. Bone tumours 0.3 0.2 (-1.4; 1.8) -0.6 (-1.3; 0.2) -1.2 (-2.8; 0.5) 0.3 (-0.8; 1.3) stable‡ n.i. 
IX. Soft tissue sarcomas 1.0* stable‡ 0.3 (-1.4; 1.0) -1.4 (-3.6; 0.8) -0.2 (-1.4; 1.1) increase‡ n.i. 
X. Germ cell tumours n.i. 0.8 (-0.7; 0.3) 0.7 (-0.5; 2.0) -0.4 (-2.2; 1.4) 2.3 (0.9; 3.7) stable‡ n.i. 
XI. Epithelial neoplasms & melanomas n.i. 2.8 (0.5; 5.1) 0.8 (0.1; 1.5) 2.5 (-0.5; 5.6) 
1983-1994:  
4.3 (1.6; 7.0) 
1996-2006:  
-5.7 (-9.1; -2.2) 
5.6* n.i. 
XII. Other malignant neoplasms n.i. n.i. 0.6 (-2.9; 4.3) 4.6 (0.1; 9.4) n.i. -7.4 (-12.2; -2.3) n.i. 
Abbreviations: ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia; CI, confidence interval; CNS, central nervous system; ICCC-3, International Classification of Childhood Cancer, third edition;  
n.a., not applicable; n.i., not indicated. * p-value>0.05 (no CI reported); ‡ no total values reported. Bold letters highlight AAPCs whose 95% CIs does not include the null value, or whose p-values<0.05. 
This table does not contain an exhaustive list of all existing reports and studies on incidence trends of childhood cancer. It includes studies and reports who investigate either all childhood cancer diagnoses 
combined or both childhood leukaemias and CNS tumours. 
